cGMP
metabolitecGMP exerts inhibitory signaling that suppresses platelet aggregation and thrombus formation.
Pathway placement
Cascade stepPlatelet adhesion & activation
Confidencemedium
RationaleInhibitory second messenger opposing platelet activation signals.
Druggability
Not assessed (no mapped human gene target).
Type I vs non-Type I discrimination
ScoresNon-Type-I-associated
R — rupture / Type-I—
C — non-Type-I63
A — assay feasibility42
E — evidence strength61
T1DI (composite)7
Specificity differential (R−C)-48.3
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 2
2anemia / acute blood lossmag 2
2hypovolemia / dehydrationmag 2
2tachyarrhythmiamag 2
2hypoxemia / respiratory failuremag 2
2hypertensive emergencymag 2
2high-demand / peri-operative stressn/a
3sudden cardiac deathmag 2
4aPCI-related periproceduralmag 2
4bstent thrombosisn/a
4cin-stent restenosismag 2
5CABG-relatedmag 1
Coverage: 10/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 24 supporting references. See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research
Literature evidence(1)
- Inhibitory effects of hydrogen on in vitro platelet activation and in vivo prevention of thrombosis formation.Life sciences · 2019 · PMID 31356907 · doi